Stability-indicating Reverse Phase-HPLC Method Development and Method Validation for Quantitative Determination of Degradation Products in Favipiravir API and Drug Product

Varada Soujanya

Department of Pharmaceutical Analysis, GITAM School of Pharmacy, GITAM (Deemed to be University), Visakhapatnam, India.

Revu Baby Nalanda *

Department of Pharmaceutical Analysis, GITAM School of Pharmacy, GITAM (Deemed to be University), Visakhapatnam, India.

*Author to whom correspondence should be addressed.


Introduction: Favipiravir is an antiviral medication shown to be broad spectrum activity against RNA viruses, and potentially treating the COVID-19.

Methodology: In this study, the HPLC method for the quantification of degradation impurities (Favipiravir Acid Impurities) were developed and validated for Favipiravir in Tablet dosage form. The specificity of the method was achieved in analytical column Agilent HPLC-C18, 5µm, (4.6 x250) mm. using a suitable mobile phase was 10 mM Phosphate buffer (pH 3.5 with orthophosphoric acid) and Acetonitrile in the Isocratic more of 70:30 v/v. The flow rate is 1.0 mL/min. the injection volume is 10 µL, detection at 320 nm in UV and total run time is 8.0 minutes. The samples were made for forced degradation under hydrolysis, oxidation, photolytic and thermal conditions. The method was validated for specific, selective, linear, robust and accurate as per the ICH guidelines.

Results and Conclusion: The linearity of the method for Impurities and the analytes was found from 25 to 150 % concentration level with the correlation coefficient (r2) > 0.999. The accuracy for impurity and the analytes was performed from 50 to 150% level concentration, and mean recovery was found from 98-102%. The analytical degradation and validated study results indicate its unstable nature in acidic, basic and thermal conditions. Therefore, this method is simple, selective and sensitive, this method can be used in pharmaceutical research and development and quality control departments.

Keywords: Favipiravir; HPLC, degradation impurities, ICH guidelines, forced degradation, stability indicating method

How to Cite

Soujanya , Varada, and Revu Baby Nalanda. 2024. “Stability-Indicating Reverse Phase-HPLC Method Development and Method Validation for Quantitative Determination of Degradation Products in Favipiravir API and Drug Product”. International Journal of TROPICAL DISEASE & Health 45 (7):10-25.


Download data is not yet available.


Furuta Y, Komeno T, Nakamura T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase, Proceedings of the Japan Academy. Ser. B: Physical and Biological Sciences. 2017; 93:449–463. Available:

Venkataraman S, Prasad B, Selvarajan R. RNA Dependent RNA Polymerases: Insights from Structure, Function and Evolution, Viruses. 2018;10:76. Available:

Hayden FG, Shindo N. Influenza virus polymerase inhibitors in clinical development, Current Opinion in Infectious Diseases. 2019;32:176–186.Available:

De Farias ST, Dos Santos Junior AP, Rêgo TG, José MV. Origin and evolution of RNA-dependent RNA polymerase. Front. Genet. 2017;8:125. Available:

Shu B, Gong P. Structural basis of viral RNA-dependent RNA polymerase catalysis and translocation, Proc. Natl. Acad. Sci. U.S.A. 2016;113.Available:

Nagata T, Lefor AK, Hasegawa M, Ishii M. Favipiravir: A new medication for the ebola virus disease pandemic. Disaster Med. Public Health Prep. 2015;9:79–81. Available:

Madelain V, Nguyen THT, Olivo A, De Lamballerie X, Guedj J, Taburet AM, Mentré F. Ebola virus infection: Review of the pharmacokinetic and pharmacodynamic properties of drugs considered for testing in human efficacy trials. Clin Pharmacokinet. 2016;55:907–923. Available:

Nguyen THT, Guedj J, Anglaret X, Laouénan C, Madelain V, Taburet AM, Baize S, Sissoko D, Pastorino B, Rodallec A, Piorkowski G, Carazo S, Conde MN, Gala JL, Bore JA, Carbonnelle C, Jacquot F, Raoul H, Malvy D, De Lamballerie XF. Mentré, on behalf of the JIKI study group, Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted. Plos Negl Trop Dis. 2017;11: e0005389. Available:

Rosenke K, Feldmann H, Westover JB, Hanley PW, Martellaro v, Feldmann F, Saturday G, Lovaglio J, Scott DP, Furuta Y, Komeno T, Gowen BB, Safronetz D. Use of favipiravir to treat lassa virus infection in Macaques. Emerg. Infect. Dis. 2018;24:1696–1699. .Available:

Delang L, Abdelnabi R, Neyts J. Favipiravir as a potential countermeasure against neglected and emerging RNA viruses. Antiviral Research. 2018;153:85–94. Available:

Bulduk İ. Comparison of HPLC and UV spectrophotometric methods for quantification of favipiravir in pharmaceutical formulations. IJPR. 2021; 20. Available:

Nadendla R, Abhinandana P. A validated high performance liquid chromatographic method for the quantification of favipiravir by PDA detector. Int. J. Life Sci. Pharma Res. 2021;11:181–188.

Bulduk i. HPLC-UV method for quantification of favipiravir in pharmaceutical formulations. Acta Chromatographica. 2021;33:209–215.

Qurt M, Eshtayyeh R, Naseef H, Rabba A, Abukhalil AD, Malkieh N, Kharouf M. Quantitative analysis of favipiravir by HPLC: Development and Validation. International Journal of Analytical Chemistry. 2023;2023:1–9. Available:

Kalshetti MS, Adlinge SG. Development and validation of HPLC method for quantification of favipiravir in tablet. Research Journal of Pharmacy and Technology. 2022;15:1319–1322.

Sharaf YA, Abd El-Fattah MH, El-Sayed HM, Hassan SA. A solvent-free HPLC method for the simultaneous determination of Favipiravir and its hydrolytic degradation product. Scientific Reports. 2023;13: 18512.

Balu PA, Paresh MS. Stability-indicating RP HPLC method development for estimation of favipiravir in bulk and pharmaceutical dosage form, World Journal of Pharmaceutical Research. 2021;10:1444–1465.

Bhukya VN, Beda DP. Implementation of green analytical principles to develop and validate the HPLC method for the separation and identification of degradation products of Panobinostat, and its characterization by using LC-QTOF-MS/MS and its in-silico toxicity prediction using ADMET software, Green Analytical Chemistry. 2024;8:100090. Available:

Divya Bhargavi P, Lolla S, Sugunan S, Shiva Gubbiyappa K, A Ali Khan, Alanazi AM, Vijay Nayak B. The simultaneous quantification of Sitagliptin and Irbesartan in rat plasma using the validated LC-MS/MS method is applied to a pharmacokinetic study. Journal of Chromatography B. 2023;1221:123677. Available:

Bhukya VN, Beda DP. Characterization of prasugrel degradation profile by several oxidative reagents using HPLC and LC-MS/MS Technique. Ajc. 2023;36:148–160. Available:

Bhukya VN, Beda DP, Gubbiyappa KS, Pathuri R. Combined green analytical principles and quality by design for ultraperformance liquid chromatography analytical method development, the characterization and In-silico toxicity prediction of Ixazomib degradation products using mass spectrometry. Green Analytical Chemistry. 2024;8: 100105. Available:

ICH Guideline: Stability testing of new drug substances and products, Q1A (R2); 2003.

ICH Guideline, Validation of analytical procedures: text and methodology Q2 (R1); 2005.

ICH Guidline: Stability testing: photostability tesing of new drug substances and products, Q1B; 1996.

Santhi Priya Lankalapalli, Vijaya Rachel K. Stability-indicating reverse phase-HPLC method development and method validation for quantitative determination of degradation impurities in sofosbuvir. Eur. Chem. Bull. 2022;11 (Regular Issue 11):1272 – 1282.